EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis

Felipe Batalini, Laercio Lopes DaSilva, Leticia Campoverde, Ana Carolina Marin Comini, Bruno Murad Carvalho, Wilson Nogueira, Hyan Silveira, Brenda J Ernst, Lida A Mina

Chinese Clinical Oncology · 2023

DOI: 10.21037/cco-22-114 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Chinese Clinical Oncology, 2023. Verfasst von Felipe Batalini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA; Department of Clinical Oncology, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: BRCA1 Protein, Ovarian Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mutations in the BRCA1/2 (BRCA) genes are associated with response to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). In addition, there are different homologous recombination deficiency (HRD) biomarkers available in clinical practice [e.g., genome-wide loss-of-heterozygosity (gLOH) and myChoice® score] that identify patients who can benefit from PARPi. Inconsistencies in biomarkers used in PARPi clinical trials make it challenging to identify clinically relevant predictive biomarkers. This study aims to compare clinically available HRD biomarkers in terms of benefits from PARPi. METHODS: We performed database search for phase II or III randomized clinical trials comparing PARPi versus chemotherapy, and meta-analysis using generic inverse variance and a Random Effects model. Patients were classified according to their HRD status: (I) BRCAm (patients with BRCA mutation of germline or somatic origin); (II) non-BRCA HRD [patients BRCA wild-type (wt) with another HRD biomarker-gLOH or myChoice®]; and (III) homologous recombination proficiency (HRP) (BRCAwt and without HRD biomarkers). From those that were BRCAwt, we compared myChoice®+ with gLOH-high. RESULTS: Five studies (3,225 patients) analyzing PARPi in first line setting were included. Patients with BRCAmut had progression-free survival (PFS) with hazard ratio (HR) 0.33 [95% confidence interval (CI): 0.30-0.43]; patients with non-BRCA HRD had a PFS HR 0.49 (95% CI: 0.37-0.65), and patients with HRP had a PFS HR 0.78 (95% CI: 0.58-1.03). Eight studies (5,529 patients) with PARPi including first line and recurrence settings were included. BRCAmut had PFS HR 0.37 (95% CI: 0.30-0.48), BRCAwt & HRD 0.45 (95% CI: 0.37-0.55) and HRP 0.70 (95% CI: 0.57-0.85). Patients with BRCAwt & myChoice® ≥42 had PFS HR 0.43 (95% CI: 0.34-0.56), similar to patients with BRCAwt & gLOH-high with PFS HR 0.42 (95% CI: 0.28-0.62). CONCLUSIONS: Patients with HRD derived significantly more benefit from PARPi when compared to patients with HRP. The benefit of PARPi in patients with HRP tumors was limited. Careful cost-effectiveness analysis, and alternative therapies or clinical trial enrollment should strongly be considered for patients with HRP tumors. Among patients with BRCAwt, a similar benefit was found in patients with gLOH-high and those myChoice®+. The clinical development of further HRD biomarkers (e.g., Sig3) may help identify more patients who benefit from PARPi.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BRCA1 ProteinOvarian NeoplasmsHumansFemaleBRCA2 ProteinPoly(ADP-ribose) Polymerase InhibitorsHomologous RecombinationBiomarkers

Stichwörter der Autor:innen

BRCA1BRCA2Homologous recombination deficiency (HRD)ovarian cancerpoly(ADP-ribose) polymerase inhibitors (PARPi)

Substanzen

BRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 ProteinPoly(ADP-ribose) Polymerase InhibitorsBiomarkers

Autor:innen und Institutionen

  • Department of Clinical Oncology, Mayo Clinic Arizona, Phoenix, AZ, USA; Department of Clinical Oncology, Harvard Medical School, Boston, MA, USA.
  • Department of Internal Medicine, National Institutes of Health, Bethesda, MD, USA.
  • Department of Internal Medicine, University of Miami, Miami, FL, USA.
  • Department of Clinical Oncology, A.C. Camargo Cancer Center, São Paulo, Brazil.
  • Faculdade de Medicina de Barbacena, Barbacena, Brazil.
  • Universidade Estadual do Piauí, Teresina, Brazil.

Zitieren

APA

Batalini, F., DaSilva, L. L., Campoverde, L., Comini, A. C. M., Carvalho, B. M., Nogueira, W., Silveira, H., Ernst, B. J., & Mina, L. A. (2023). Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis. Chinese Clinical Oncology. https://doi.org/10.21037/cco-22-114

Vancouver

Batalini F, DaSilva LL, Campoverde L, Comini ACM, Carvalho BM, Nogueira W, et al. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis. Chinese Clinical Oncology. 2023. doi:10.21037/cco-22-114

BibTeX
@article{Batalini2023,
  author = {Batalini, Felipe and DaSilva, Laercio Lopes and Campoverde, Leticia and Comini, Ana Carolina Marin and Carvalho, Bruno Murad and Nogueira, Wilson and Silveira, Hyan and Ernst, Brenda J and Mina, Lida A},
  title = {Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis},
  journal = {Chinese Clinical Oncology},
  year = {2023},
  doi = {10.21037/cco-22-114}
}
Kostenlos starten →